Netherlands
# |
Name |
EBIT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
24.59%
|
Dec. 31, 2023 | USD 44.64 | 0.29% |
|
Netherlands |
|
2 |
-1.21%
|
Dec. 31, 2023 | USD 27.61 | 1.08% |
|
Netherlands |
|
3 |
-2.47%
|
Dec. 31, 2023 | USD 8.76 | -0.46% |
|
Netherlands |
|
4 |
-24.76%
|
Dec. 31, 2023 | USD 662.53 | -0.67% |
|
Netherlands |
|
5 |
-356.22%
|
Dec. 31, 2023 | USD 40.94 | -1.52% |
|
Netherlands |
|
6 |
-408.50%
|
Dec. 31, 2023 | USD 2.12 | -1.40% |
|
Netherlands |
|
7 |
-615.97%
|
Dec. 31, 2023 | USD 0.98 | -1.01% |
|
Netherlands |
|
8 |
-1,386.15%
|
Dec. 31, 2023 | USD 22.29 | 2.39% |
|
Netherlands |
|
9 |
-1,672.66%
|
Dec. 31, 2023 | USD 15.74 | -0.32% |
|
Netherlands |
The Biotechnology company in Netherlands with the highest EBIT Margin is Qiagen N.V. (NYSE: QGEN) at 24.59%.
The Biotechnology company in Netherlands with the lowest EBIT Margin is uniQure N.V. (NasdaqGS: QURE) at -1,672.66%.
The top 10 Biotechnology companies in Netherlands by EBIT Margin are Qiagen N.V., Koninklijke Philips N.V., Pharming Group N.V., argenx SE, Merus N.V., ProQR Therapeutics N.V., LAVA Therapeutics N.V., NewAmsterdam Pharma Company N.V. and uniQure N.V..
The bottom 10 Biotechnology companies in Netherlands by EBIT Margin are uniQure N.V., NewAmsterdam Pharma Company N.V., LAVA Therapeutics N.V., ProQR Therapeutics N.V., Merus N.V., argenx SE, Pharming Group N.V., Koninklijke Philips N.V. and Qiagen N.V..